Skip to main content Accessibility help
×
Home
Hostname: page-component-684899dbb8-mhx7p Total loading time: 0.726 Render date: 2022-05-23T09:23:25.772Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "useNewApi": true }

Book contents

22 - Management of cancer of the prostate

Published online by Cambridge University Press:  05 November 2015

Jim Barber
Affiliation:
Velindre Cancer Centre, Velindre Hospital, Cardiff, UK
John Staffurth
Affiliation:
Velindre Cancer Centre, Velindre Hospital, Cardiff, UK
Louise Hanna
Affiliation:
Velindre Cancer Centre, Velindre Hospital, Cardiff
Tom Crosby
Affiliation:
Velindre Cancer Centre, Velindre Hospital, Cardiff
Fergus Macbeth
Affiliation:
Velindre Cancer Centre, Velindre Hospital, Cardiff
Get access

Summary

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bill-Axelson, A., Holmberg, L., Ruutu, M., et al. (2005). Radical prostatectomy versus watchful waiting in early prostate cancer. N. Engl. J. Med., 352, 1977–1984.CrossRefGoogle ScholarPubMed
Bolla, M., de Reijke, T. M., Van Tienhoven, G., et al. (2009). Duration of androgen suppression in the treatment of prostate cancer. N. Engl. J. Med., 360, 2516–2527.CrossRefGoogle ScholarPubMed
Bolla, M, van Poppel, H., Tombal, B., et al. (2012). Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet, 380, 2018–2027.CrossRefGoogle Scholar
Buyyounouski, M. K., Hanlon, A. L., Eisenberg, D. F., et al. (2005). Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 63, 1455–1462.CrossRefGoogle ScholarPubMed
Dearnaley, D. P., Syndikus, I., Sumo, G., et al. (2012). Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol., 13, 43–54.CrossRefGoogle ScholarPubMed
de Bono, J. S., Oudard, S., Ozguroglu, M., et al. (2010). TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet, 376, 1147–1154.CrossRefGoogle ScholarPubMed
Guerrero Urbano, T., Khoo, V., Staffurth, J., et al. (2010). Intensity-modulated radiotherapy allows escalation of the radiation dose to the pelvic lymph nodes in patients with locally advanced prostate cancer: preliminary results of a phase I dose escalation study. Clin. Oncol. (R. Coll. Radiol.), 22, 236–244.CrossRefGoogle ScholarPubMed
Hoskin, P. J., Rojas, A. M., Bownes, P. J., et al. (2012). Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother. Oncol., 103, 217–222.CrossRefGoogle ScholarPubMed
James, N. D., Spears, M. R., Clarke, N. W., et al. (2014). Survival with newly diagnosed metastatic prostate cancer in the ‘docetaxel era’: data from 917 patients in the control arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur. Oncol., [Epub ahead of print]: pii: S0302–2838(14)00969–5. doi: 10.1016/j.eururo.2014.09.032.Google Scholar
Lawton, C. A., Desilvio, M. and Roach, M. 3rd. (2007). An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to total androgen suppression: updated analysis of RTOG 94–13, with emphasis on unexpected hormone/radiation interactions. Int. J. Radiat. Oncol. Biol. Phys., 69, 646–655.CrossRefGoogle ScholarPubMed
NICE. (2014). Prostate Cancer: Diagnosis and Treatment. Clinical Guideline. Commissioned by the National Institute for Health and Care Excellence.Cardiff: National Collaborating Centre for Cancer.
Parker, C., Nilsson, S., Heinrich, D., et al. (2013). Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med., 369, 213–223.CrossRefGoogle ScholarPubMed
Prostate Cancer Risk Management Programme. (2006). Undertaking a Trans-rectal Ultrasound Guided Biopsy of the Prostate.Sheffield: NHS Cancer Screening Progamme.
Saad, F., Gleason, D. M., Murray, R., et al. (2004). Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Natl Cancer Inst., 96, 879–882.Google ScholarPubMed
Tannock, I. F., de Wit, R., Berry, W. R., et al. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med., 351, 1502–1512.CrossRefGoogle ScholarPubMed
UICC. (2009). TNM Classification of Malignant Tumours, ed. Sobin, L. H., Gospodariowicz, M. and Wittekind, Ch., 7th edn. Chichester: Wiley-Blackwell.
van As, N. J., de Souza, N. M., Riches, S. F., et al. (2009). A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance. Eur. Urol., 56, 981–987.CrossRefGoogle ScholarPubMed
Warde, P., Mason, M. D., Ding, K., et al. (2011), Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol., 378, 2104–2111.Google ScholarPubMed
Wirth, M. P., See, W. A., McLeod, D. G., et al. (2004). Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J. Urol., 172, 1865–1870.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×